- Home
- LNKB vs RIGL Comparison
LNKB vs RIGL Comparison
Compare LNKB & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- RIGL
- Stock Information
- Founded
- LNKB 2018
- RIGL 1996
- Country
- LNKB United States
- RIGL United States
- Employees
- LNKB N/A
- RIGL N/A
- Industry
- LNKB
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- RIGL Health Care
- Exchange
- LNKB Nasdaq
- RIGL Nasdaq
- Market Cap
- LNKB 261.4M
- RIGL 537.6M
- IPO Year
- LNKB N/A
- RIGL 2000
- Fundamental
- Price
- LNKB $7.29
- RIGL $36.50
- Analyst Decision
- LNKB Strong Buy
- RIGL Buy
- Analyst Count
- LNKB 1
- RIGL 6
- Target Price
- LNKB $9.00
- RIGL $39.83
- AVG Volume (30 Days)
- LNKB 122.5K
- RIGL 561.4K
- Earning Date
- LNKB 10-27-2025
- RIGL 11-04-2025
- Dividend Yield
- LNKB 4.14%
- RIGL N/A
- EPS Growth
- LNKB 512.12
- RIGL 2698.26
- EPS
- LNKB 1.03
- RIGL 6.20
- Revenue
- LNKB $122,594,000.00
- RIGL $282,076,000.00
- Revenue This Year
- LNKB $18.38
- RIGL $59.93
- Revenue Next Year
- LNKB N/A
- RIGL N/A
- P/E Ratio
- LNKB $7.04
- RIGL $5.83
- Revenue Growth
- LNKB 42.32
- RIGL 79.13
- 52 Week Low
- LNKB $6.09
- RIGL $14.47
- 52 Week High
- LNKB $7.98
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- LNKB 59.12
- RIGL 64.64
- Support Level
- LNKB $6.97
- RIGL $28.08
- Resistance Level
- LNKB $7.16
- RIGL $39.56
- Average True Range (ATR)
- LNKB 0.19
- RIGL 1.98
- MACD
- LNKB 0.03
- RIGL 0.91
- Stochastic Oscillator
- LNKB 81.13
- RIGL 74.84
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.